Selected research
Industry Research
Microbial Therapeutic Product Industry Research Report 2026
Market perspective
The global Microbial Therapeutic Product market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Microbial Therapeutic Product market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Microbial Therapeutic Product market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Microbial Therapeutic Product market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Microbial Therapeutic Product include Novartis, Roche, Eli Lilly and Company, Pfizer, Amgen Inc., Viatris, Sanofi S.A., Novo Nordisk A/S and Merck & Co. Inc., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Microbial Therapeutic Product market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Microbial Therapeutic Product.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Microbial Therapeutic Product Market by Company
Novartis
Roche
Eli Lilly and Company
Pfizer
Amgen Inc.
Viatris
Sanofi S.A.
Novo Nordisk A/S
Merck & Co. Inc.
Intas Pharmaceuticals Ltd.
Dr. Reddy’s Laboratories Ltd.
Bristol-Myers Squibb Company
Boehringer Ingelheim
Biocon
Abbot Laboratories
Microbial Therapeutic Product Segment by Type
Single Use Pre-Filled Injection/Injector Pen
Multi-use Injectors
Others
Microbial Therapeutic Product Segment by Application
Oncology
Haematological Disorders
Immunological Disorders
Allergic Diseases
Metabolic Disorders
Infectious Diseases
Others
Microbial Therapeutic Product Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbial Therapeutic Product market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Microbial Therapeutic Product and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbial Therapeutic Product.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Microbial Therapeutic Product companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Single Use Pre-Filled Injection/Injector Pen
- Multi-use Injectors
- Others
Applications
- Oncology
- Haematological Disorders
- Immunological Disorders
- Allergic Diseases
- Metabolic Disorders
- Infectious Diseases
- Others
Companies covered
- Novartis
- Roche
- Eli Lilly and Company
- Pfizer
- Amgen Inc.
- Viatris
- Sanofi S.A.
- Novo Nordisk A/S
- Merck & Co. Inc.
- Intas Pharmaceuticals Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Bristol-Myers Squibb Company
- Boehringer Ingelheim
- Biocon
- Abbot Laboratories
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Microbial Therapeutic Product by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Single Use Pre-Filled Injection/Injector Pen
- 2.2.3 Multi-use Injectors
- 2.2.4 Others
- 2.3 Microbial Therapeutic Product by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Oncology
- 2.3.3 Haematological Disorders
- 2.3.4 Immunological Disorders
- 2.3.5 Allergic Diseases
- 2.3.6 Metabolic Disorders
- 2.3.7 Infectious Diseases
- 2.3.8 Others
- 2.4 Assumptions and Limitations
3 Microbial Therapeutic Product Breakdown Data by Type
- 3.1 Global Microbial Therapeutic Product Historic Market Size by Type (2021-2026)
- 3.2 Global Microbial Therapeutic Product Forecasted Market Size by Type (2027-2032)
4 Microbial Therapeutic Product Breakdown Data by Application
- 4.1 Global Microbial Therapeutic Product Historic Market Size by Application (2021-2026)
- 4.2 Global Microbial Therapeutic Product Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Microbial Therapeutic Product Market Perspective (2021-2032)
- 5.2 Global Microbial Therapeutic Product Growth Trends by Region
- 5.2.1 Global Microbial Therapeutic Product Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Microbial Therapeutic Product Historic Market Size by Region (2021-2026)
- 5.2.3 Microbial Therapeutic Product Forecasted Market Size by Region (2027-2032)
- 5.3 Microbial Therapeutic Product Market Dynamics
- 5.3.1 Microbial Therapeutic Product Industry Trends
- 5.3.2 Microbial Therapeutic Product Market Drivers
- 5.3.3 Microbial Therapeutic Product Market Challenges
- 5.3.4 Microbial Therapeutic Product Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Microbial Therapeutic Product Players by Revenue
- 6.1.1 Global Top Microbial Therapeutic Product Players by Revenue (2021-2026)
- 6.1.2 Global Microbial Therapeutic Product Revenue Market Share by Players (2021-2026)
- 6.2 Global Microbial Therapeutic Product Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Microbial Therapeutic Product Head Office and Area Served
- 6.4 Global Microbial Therapeutic Product Players, Product Type & Application
- 6.5 Global Microbial Therapeutic Product Manufacturers Established Date
- 6.6 Global Microbial Therapeutic Product Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Microbial Therapeutic Product Market Size (2021-2032)
- 7.2 North America Microbial Therapeutic Product Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Microbial Therapeutic Product Market Size by Country (2021-2026)
- 7.4 North America Microbial Therapeutic Product Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Microbial Therapeutic Product Market Size (2021-2032)
- 8.2 Europe Microbial Therapeutic Product Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Microbial Therapeutic Product Market Size by Country (2021-2026)
- 8.4 Europe Microbial Therapeutic Product Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Microbial Therapeutic Product Market Size (2021-2032)
- 9.2 Asia-Pacific Microbial Therapeutic Product Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Microbial Therapeutic Product Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Microbial Therapeutic Product Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Microbial Therapeutic Product Market Size (2021-2032)
- 10.2 South America Microbial Therapeutic Product Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Microbial Therapeutic Product Market Size by Country (2021-2026)
- 10.4 South America Microbial Therapeutic Product Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Microbial Therapeutic Product Market Size (2021-2032)
- 11.2 Middle East & Africa Microbial Therapeutic Product Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Microbial Therapeutic Product Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Microbial Therapeutic Product Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Novartis
- 12.1.1 Novartis Company Information
- 12.1.2 Novartis Business Overview
- 12.1.3 Novartis Revenue in Microbial Therapeutic Product Business (2021-2026)
- 12.1.4 Novartis Microbial Therapeutic Product Product Portfolio
- 12.1.5 Novartis Recent Developments
- 12.2 Roche
- 12.2.1 Roche Company Information
- 12.2.2 Roche Business Overview
- 12.2.3 Roche Revenue in Microbial Therapeutic Product Business (2021-2026)
- 12.2.4 Roche Microbial Therapeutic Product Product Portfolio
- 12.2.5 Roche Recent Developments
- 12.3 Eli Lilly and Company
- 12.3.1 Eli Lilly and Company Company Information
- 12.3.2 Eli Lilly and Company Business Overview
- 12.3.3 Eli Lilly and Company Revenue in Microbial Therapeutic Product Business (2021-2026)
- 12.3.4 Eli Lilly and Company Microbial Therapeutic Product Product Portfolio
- 12.3.5 Eli Lilly and Company Recent Developments
- 12.4 Pfizer
- 12.4.1 Pfizer Company Information
- 12.4.2 Pfizer Business Overview
- 12.4.3 Pfizer Revenue in Microbial Therapeutic Product Business (2021-2026)
- 12.4.4 Pfizer Microbial Therapeutic Product Product Portfolio
- 12.4.5 Pfizer Recent Developments
- 12.5 Amgen Inc.
- 12.5.1 Amgen Inc. Company Information
- 12.5.2 Amgen Inc. Business Overview
- 12.5.3 Amgen Inc. Revenue in Microbial Therapeutic Product Business (2021-2026)
- 12.5.4 Amgen Inc. Microbial Therapeutic Product Product Portfolio
- 12.5.5 Amgen Inc. Recent Developments
- 12.6 Viatris
- 12.6.1 Viatris Company Information
- 12.6.2 Viatris Business Overview
- 12.6.3 Viatris Revenue in Microbial Therapeutic Product Business (2021-2026)
- 12.6.4 Viatris Microbial Therapeutic Product Product Portfolio
- 12.6.5 Viatris Recent Developments
- 12.7 Sanofi S.A.
- 12.7.1 Sanofi S.A. Company Information
- 12.7.2 Sanofi S.A. Business Overview
- 12.7.3 Sanofi S.A. Revenue in Microbial Therapeutic Product Business (2021-2026)
- 12.7.4 Sanofi S.A. Microbial Therapeutic Product Product Portfolio
- 12.7.5 Sanofi S.A. Recent Developments
- 12.8 Novo Nordisk A/S
- 12.8.1 Novo Nordisk A/S Company Information
- 12.8.2 Novo Nordisk A/S Business Overview
- 12.8.3 Novo Nordisk A/S Revenue in Microbial Therapeutic Product Business (2021-2026)
- 12.8.4 Novo Nordisk A/S Microbial Therapeutic Product Product Portfolio
- 12.8.5 Novo Nordisk A/S Recent Developments
- 12.9 Merck & Co. Inc.
- 12.9.1 Merck & Co. Inc. Company Information
- 12.9.2 Merck & Co. Inc. Business Overview
- 12.9.3 Merck & Co. Inc. Revenue in Microbial Therapeutic Product Business (2021-2026)
- 12.9.4 Merck & Co. Inc. Microbial Therapeutic Product Product Portfolio
- 12.9.5 Merck & Co. Inc. Recent Developments
- 12.10 Intas Pharmaceuticals Ltd.
- 12.10.1 Intas Pharmaceuticals Ltd. Company Information
- 12.10.2 Intas Pharmaceuticals Ltd. Business Overview
- 12.10.3 Intas Pharmaceuticals Ltd. Revenue in Microbial Therapeutic Product Business (2021-2026)
- 12.10.4 Intas Pharmaceuticals Ltd. Microbial Therapeutic Product Product Portfolio
- 12.10.5 Intas Pharmaceuticals Ltd. Recent Developments
- 12.11 Dr. Reddy’s Laboratories Ltd.
- 12.11.1 Dr. Reddy’s Laboratories Ltd. Company Information
- 12.11.2 Dr. Reddy’s Laboratories Ltd. Business Overview
- 12.11.3 Dr. Reddy’s Laboratories Ltd. Revenue in Microbial Therapeutic Product Business (2021-2026)
- 12.11.4 Dr. Reddy’s Laboratories Ltd. Microbial Therapeutic Product Product Portfolio
- 12.11.5 Dr. Reddy’s Laboratories Ltd. Recent Developments
- 12.12 Bristol-Myers Squibb Company
- 12.12.1 Bristol-Myers Squibb Company Company Information
- 12.12.2 Bristol-Myers Squibb Company Business Overview
- 12.12.3 Bristol-Myers Squibb Company Revenue in Microbial Therapeutic Product Business (2021-2026)
- 12.12.4 Bristol-Myers Squibb Company Microbial Therapeutic Product Product Portfolio
- 12.12.5 Bristol-Myers Squibb Company Recent Developments
- 12.13 Boehringer Ingelheim
- 12.13.1 Boehringer Ingelheim Company Information
- 12.13.2 Boehringer Ingelheim Business Overview
- 12.13.3 Boehringer Ingelheim Revenue in Microbial Therapeutic Product Business (2021-2026)
- 12.13.4 Boehringer Ingelheim Microbial Therapeutic Product Product Portfolio
- 12.13.5 Boehringer Ingelheim Recent Developments
- 12.14 Biocon
- 12.14.1 Biocon Company Information
- 12.14.2 Biocon Business Overview
- 12.14.3 Biocon Revenue in Microbial Therapeutic Product Business (2021-2026)
- 12.14.4 Biocon Microbial Therapeutic Product Product Portfolio
- 12.14.5 Biocon Recent Developments
- 12.15 Abbot Laboratories
- 12.15.1 Abbot Laboratories Company Information
- 12.15.2 Abbot Laboratories Business Overview
- 12.15.3 Abbot Laboratories Revenue in Microbial Therapeutic Product Business (2021-2026)
- 12.15.4 Abbot Laboratories Microbial Therapeutic Product Product Portfolio
- 12.15.5 Abbot Laboratories Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst